Efficacy of adjuvant 5-fluorouracil therapy for patients with emast-positive stage ii/iii colorectal cancer

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Hamaya, Yasushi ^a   Guarinos, Carla ^a,b   Tseng Rogenski, Stephanie S ^a   Iwaizumi, Moriya ^a   Das, Ritabrata ^c   Jover, Rodrigo ^b   Castells, Antoni ^d   Llor, Xavier ^e   Andreu, Montserrat ^f   Carethers, John M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c UNIVERSITY OF MICHIGAN   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEIN MSH3; ANTINEOPLASTIC ANTIMETABOLITE; MICROSATELLITE DNA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; ELEVATED MICROSATELLITE ALTERATIONS AT SELECTED TETRANUCLEOTIDE REPEAT; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC MARKER; HUMAN; IN VITRO STUDY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PROTEIN FUNCTION; ADJUVANT CHEMOTHERAPY; COLORECTAL NEOPLASMS; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930629787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127591     Document Type: Article

References (31)

1. Carethers JM. Current and future role of the gastroenterologist in GI cancer management. J Digest Cancer Rep 2013; 1:78-81.
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64:104-17. doi: 10.3322/caac.21220 PMID: 24639052
3. Boland CR, Sinicrope FA, Brenner DE, Carethers JM. Colorectal cancer prevention and treatment. Gastroenterology 2000; 118:S115-S128. PMID: 10868902
4. Graham JS, Cassidy J. Adjuvant therapy in colon cancer. Expert Rev Anticancer Ther 2012; 12:99-109. doi: 10.1586/era.11.189 PMID: 22149436
5. Carethers JM. Systemic treatment of advanced colorectal cancer - tailoring therapy to the tumor. Ther Adv Gastroenterol 2008; 1:33-42.
6. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117:123-131. PMID: 10381918
7. Jo W-S, Carethers JM. Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomarkers 2006; 2:51-60. PMID: 17192059
8. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutSαrecognizes 5-fluoruracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004; 127:1678-1684. PMID: 15578504
9. Tajima A, Iwaizumi M, Tseng-Rogenski S, Cabrera BL, Carethers JM. Both hMutSα and hMutSβ complexes participate in 5-fluorouracil cytotoxicity. PLoS One 2011; 6:e28117. doi: 10.1371/journal.pone.0028117 PMID: 22164234
10. Iwaizumi M, Tseng-Rogenski S, Carethers JM. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther 2011; 12:756-764. doi: 10.4161/cbt.12.8.17169 PMID: 21814034
11. Chung H, Chaudhry J, Lopez CG, Carethers JM. Cyclin E and histone H3 are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner. Cancer Biol Ther 2010; 10:1147-1156. PMID: 20930505
12. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135:1079-1099. doi: 10.1053/j.gastro.2008.07.076 PMID: 18773902
13. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138:2073-2087. doi: 10.1053/j.gastro.2009.12.064 PMID: 20420947
14. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer. Gastroenterology 2004; 126: 394-401.
15. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55:848-855.
16. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009; 45:365-73. doi: 10.1016/j.ejca.2008.07.016 PMID: 18722765
17. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004; 109:468-71. PMID: 14961589
18. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-257. PMID: 12867608
19. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28:3219-3226.
20. Haugen AC, Goel A, Yamada K, Marra G, Nguyen TP, Nagasaka T, et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res 2008; 68:8465-8472. doi: 10.1158/0008-5472.CAN-08-0002 PMID: 18922920
21. Devaraj B, Lee A, Cabrera BL, Miyai K, Luo L, Ramamoorthy S, et al. Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg 2010; 14:1521-1528.
22. Lee S-Y, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang DY, et al. Elevated microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasia. Gastroenterology 2010; 139:1519-1525.
23. Yamada K, Kanazawa S, Koike J, Sugiyama H, Xu C, Funahashi K, et al. Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol Rep 2010; 23:551-561. PMID: 20043121
24. Hile SE, Shabashev S, Eckert KA. Tumor-specific microsatellite instability: do distinct mechanisms underlie the MSI-L and EMAST phenotypes? Mutat Res 2013; 743-744:67-77.
25. Garcia M, Choi C, Kim HR, Daoud Y, Toiyama Y, Takahashi M, et al. Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology 2012; 143:48-50. doi: 10.1053/j.gastro.2012.03.034 PMID: 22465427
26. Tseng-Rogenski S, Chung H, Wilk MB, Zhang S, Iwaizumi M, Carethers JM. Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. PLoS One 2012; 7:e50616. doi: 10.1371/journal.pone.0050616 PMID: 23226332
27. Campregher C, Schmid G, Ferk F, Knasmüller S, Khare V, Kortüm B, et al. MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PLoS One 2012; 7:e50541. doi: 10.1371/journal.pone.0050541 PMID: 23209772
28. Tseng-Rogenski S, Hamaya Y, Choi DY, Carethers JM. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology 2015; 148:579-589.
29. Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, et al. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS One 2014; 9:e100461. doi: 10.1371/journal.pone.0100461 PMID: 24956473
30. Carethers JM. Differentiating Lynch-like from Lynch syndrome. Gastroenterology 2014; 146:602-604. doi: 10.1053/j.gastro.2014.01.041 PMID: 24468183
31. Carethers JM, Koi M, Tseng-Rogenski S. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes 2015; 6:185-205.